Clinical Trial

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-08; most recent amendment 2026-05-04.
Status change: Recruiting → Completed 2026-03-26
Trial Details
NCT Number NCT07171619
Lead Sponsor SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions Healthy
Enrollment 24 participants
Start Date 2025-08-21
Primary Completion 2025-11-10 (estimated)
Study Completion 2025-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-08